StockData
Johnson & Johnson logo

Johnson & Johnson (JNJ) operating KPIs

JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3043% above fair value
$273.20−2.00 (-0.73%)

Close on Oct 30, 2026Market cap $658.38BP/E 31.7Yield 1.88%

Johnson & Johnson other Oncology medicines — Worldwide operational (constant-currency) growth YoY (%) (%)

Form 8-K EX-99.2 Segment Sales Schedule

Latest, FY2025
17.5%
Period ended Dec 28, 2025
Change on a year earlier
-76.8 pts
94.3% in FY2024
History
8 years
Since FY2017
Sources
8
Documents cited below

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedOther Oncology medicines — Worldwide operational (constant-currency) growth YoY (%) (%)Year on yearSource
FY2025Dec 28, 202517.5%-76.8 ptsForm 8-K (a2025q4exhibit991.htm, filed 2026-01-21) ↗
FY2024Dec 29, 202494.3%–Form 8-K (a2024q4exhibit991.htm, filed 2025-01-22) ↗
FY2022Jan 1, 20236.0%+37.5 ptsForm 8-K (a2022q4exhibit991.htm, filed 2023-01-24) ↗
FY2021Jan 2, 2022-31.5%-33.7 ptsForm 8-K (a2021q4exhibit991.htm, filed 2022-01-25) ↗
FY2020Jan 3, 20212.2%-26.4 ptsForm 8-K (a2020q4exhibit991.htm, filed 2021-01-26) ↗
FY2019Dec 29, 201928.6%+12.2 ptsForm 8-K (a2019q4exhibit991.htm, filed 2020-01-22) ↗
FY2018Dec 30, 201816.4%+16.0 ptsForm 8-K (a2018q4exhibit9915.htm, filed 2019-01-22) ↗
FY2017Dec 31, 20170.4%–Form 8-K (a8k2017q4exhibit9915.htm, filed 2018-01-23) ↗

Breakdown

What makes up other oncology medicines — worldwide operational (constant-currency) growth yoy (%)

Cite this data

StockData. (2026). Johnson & Johnson Other Oncology medicines — Worldwide operational (constant-currency) growth YoY (%) (%), annual FY2017–FY2025 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug_other_onc_ops_yoy

See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.